Kiran Bambha

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu, Stephen A. Harrison, Sven Francque et al. · Gastroenterology · 2016 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a united states community

Kiran Bambha, W. Ray Kim, Jayant A. Talwalkar et al. · Gastroenterology · 2003 · 452 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +9

Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis

Kiran Bambha, W. Ray Kim, Rachel Pedersen et al. · Gut · 2008 · 259 citations

Medicine, Biostatistics, Hematology +16